Multiple lines of clinical evidence have suggested that ATTRv amyloidosis patients carrying TTR mutations may have vastly different clinical manifestations, disease age of onset, progressiveness, mutant penetrance, and drug response, posing clinical challenges to precise diagnosis and treatment options. This evidence concerns the gene TTR and familial amyloid neuropathy.